However, VEGF-A, as measured using an Enzyme-linked immunosorbent assay that recognizes all VEGF-A isoforms, was not predictive in a comprehensive evaluation of four phase III trials of BEV in CRC, NSCLC, and renal cancer [32]. This evidence concerns the gene VEGFA and renal carcinoma.